Novartis (BMV:NOVN N) - Aandelenkoers, Nieuws & Analyse

NOVN N Overzicht aandelen

Novartis AG houdt zich bezig met onderzoek, ontwikkeling, productie en marketing van gezondheidsproducten in Zwitserland en internationaal. Meer informatie

NOVN N fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	1/6
Prestaties in het verleden	5/6
Financiële gezondheid	4/6
Dividenden	5/6

Beloningen

Verhandeld tegen 50.8% onder onze schatting van de reële waarde

De winst groeide het afgelopen jaar met 62.3%

Betaalt een betrouwbaar dividend van 3.43%

Risicoanalyse

Aandelen zijn zeer illiquide

Grote eenmalige posten die de financiële resultaten beïnvloeden

Novartis AG Concurrenten

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.9b

Roche Holding

SWX:ROG

CHF 204.3b

AstraZeneca

LSE:AZN

UK£162.4b

Merck

NYSE:MRK

US$250.9b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Novartis
Historische aandelenkoersen
Huidige aandelenkoers	CHF 2,236.00
52 Week Hoogtepunt	CHF 2,236.00
52 Week Laag	CHF 2,236.00
Bèta	0.51
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	27.44%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	NOVN N	MX Pharmaceuticals	MX Markt
7D	0%	-1.3%	-0.3%
1Y	n/a	-19.3%	-4.0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe NOVN N presteerde ten opzichte van de MX Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe NOVN N presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is NOVN N's price volatile compared to industry and market?
NOVN N volatility
NOVN N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.2%
10% least volatile stocks in MX Market	2.7%

Stabiele aandelenkoers: De aandelenkoers van NOVN N is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van NOVN N in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1996	76,057	Vas Narasimhan	www.novartis.com

Novartis AG houdt zich bezig met onderzoek, ontwikkeling, productie en marketing van gezondheidsproducten in Zwitserland en internationaal. Het bedrijf biedt geneesmiddelen op recept voor patiënten en artsen. Het bedrijf levert ook Pluvicto, lutetium Lu 177 vipivotide tetraxetan, geïndiceerd voor de behandeling van volwassen patiënten met prostaat-specifiek membraanantigeen (PSMA)-positieve uitgezaaide castratieresistente prostaatkanker; en Lutathera, lutetium Lu 177 dotataat, een geneesmiddel op recept dat wordt gebruikt voor de behandeling van volwassenen en kinderen van 12 jaar en ouder met gastroenteropancreatische neuro-endocriene tumoren.

Novartis AG Samenvatting

Hoe verhouden de winst en inkomsten van Novartis zich tot de beurswaarde?
NOVN N fundamentele statistieken
Marktkapitalisatie	Mex$4.29t
Inkomsten(TTM)	Mex$240.87b
Inkomsten(TTM)	Mex$1.02t

17.8x

Koers/Winstverhouding

4.2x

P/S-verhouding

Is NOVN N overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
NOVN N resultatenrekening (TTM)
Inkomsten	US$49.94b
Kosten van inkomsten	US$12.07b
Brutowinst	US$37.87b
Overige uitgaven	US$26.11b
Inkomsten	US$11.76b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Jan 31, 2025

Winst per aandeel (EPS)	5.88
Brutomarge	75.83%
Nettowinstmarge	23.55%
Schuld/Eigen Vermogen Verhouding	69.8%

Hoe presteerde NOVN N op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

3.4%

Huidig dividendrendement

68%

Uitbetalingsratio

NOVN N Overzicht aandelen

Beloningen

Risicoanalyse

Novartis AG Concurrenten

BMV:LAB B

Mex$24.9b

SWX:ROG

CHF 204.3b

LSE:AZN

UK£162.4b

NYSE:MRK

US$250.9b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Novartis AG (SWX:NOVN) acquired Kate Therapeutics, Inc. in a transaction valued at $1.1 billion.

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Recent updates

Novartis AG (SWX:NOVN) acquired Kate Therapeutics, Inc. in a transaction valued at $1.1 billion.

Novartis' Scemblix® Receives Approval from US Food and Drug Administration

Novartis Raises Earnings Guidance for the Fiscal Year 2024

Novartis AG, Annual General Meeting, Mar 07, 2025

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

Novartis Announces Positive Topline Results from Twice-Yearly Leqvio (Inclisiran) in the Phase III V-Mono Study

Siemens Healthineers Offers to Buy Novartis Molecular Imaging Business

Novartis Receives FDA Accelerated Approval for Fabhalta (iptacopan)

Novartis AG to Report Q4, 2024 Results on Jan 31, 2025

Novartis AG Presents Latest Phase III Fabhalta®? (iptacopan) Data in C3 Glomerulopathy (C3G)

Novartis AG (SWX:NOVN) entered into an agreement to acquire Mariana Oncology, Inc. from Atlas Venture L.P., Access Biotechnology, RA Capital Management, L.P., Deep Track Capital, LP, Forbion Capital Partners B.V. and others for $1.8 billion.

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).

Bausch & Lomb Ireland completed the acquisition of ophthalmology assets of Novartis AG from Novartis AG for $2.5 billion.

Sandoz, Novartis Division, Receives European Commission Approval for Tyruko (Natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe

Novartis Radioligand Therapy Lutathera® Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival in First Line Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Novartis AG Issues Voluntary Nationwide Recall of One Lot of Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

Novartis AG Announces Executive Changes